Notably, CAR-EVs substantially inhibited tumor growth without cytokine release syndrome, which is the primary side effect of CAR-T cell therapy, and the tumor-inhibiting efficacy did not decrease with the treatment of PD-1:PD-L1 blockade [69]. The gene discussed is PDCD1; the disease is neoplasm.